Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial
Lists
Only you see this
Abstract
Vonoprazan reduced heartburn symptoms in subjects diagnosed with non-erosive reflux disease, with the benefit appearing to begin as early as the first day of therapy. Treatment effect persisted after the initial 4-week placebo-controlled period throughout the 20-week extension period. The 2 vonoprazan doses (10 mg and 20 mg) were similar in efficacy. (ClinicalTrials.gov: NCT05195528).
BibTeX
@inproceedings{laine2024vonoprazan,
author = {Loren Laine and Stuart J. Spechler and Rena Yadlapati and Felice Schnoll‐Sussman and Neila Smith and Eckhard Leifke and Tom M. Harris and Barbara Hunt and Ronnie Fass and Philip O. Katz},
title = {{Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial}},
booktitle = {Clinical},
year = {2024},
doi = {10.1016/j.cgh.2024.05.004},
}Loading related content...